Literature DB >> 8115413

Ibogaine reduces preference for cocaine consumption in C57BL/6By mice.

H Sershen1, A Hashim, A Lajtha.   

Abstract

After a period of forced exposure to 300 mg/l cocaine HCl in drinking water for a period of one week, followed by forced exposure to 200 mg/l cocaine for an additional week, male C57BL/6By mice developed a preference for cocaine when given a choice of drinking either water or a solution containing cocaine (200 mg/l). The mean daily intake of cocaine during the choice period was 26 +/- 1 mg/kg or, when expressed as the ratio of cocaine over total fluid intake, represented a cocaine preference of 71 +/- 2%. Administration of ibogaine HCl (40 mg/kg, two injections 6 h apart) two weeks after the beginning of the choice period reduced the cocaine preference for at least five days; the mean daily intake of cocaine was reduced by 38% (to 16 +/- 1 mg/kg per day; p < 0.05) and cocaine preference was reduced to 41 +/- 2% (cocaine fluid consumption/total fluid intake). An acute challenge injection of cocaine (25 mg/kg SC) produced a significant increase in cocaine-induced locomotor activity and stereotypy in mice previously exposed to cocaine in their drinking water (cocaine choice group). Five days after ibogaine administration, locomotor and stereotypy activity were significantly lower after a challenge injection of cocaine (25 mg/kg SC). Brain levels of cocaine 35 min after the challenge injection of cocaine were approximately 25% higher in ibogaine-treated mice (7.2 +/- 0.5 and 9.3 +/- 0.8 micrograms/g wet wt for water vs. mice treated with water plus ibogaine and 9.3 +/- 0.2 and 11.8 +/- 0.7 micrograms/g wet wt for cocaine drinking vs. cocaine drinking plus ibogaine treatment).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8115413     DOI: 10.1016/0091-3057(94)90105-8

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  7 in total

1.  Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration.

Authors:  Sebastien Carnicella; Dao-Yao He; Quinn V Yowell; Stanley D Glick; Dorit Ron
Journal:  Addict Biol       Date:  2010-10       Impact factor: 4.280

2.  Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption.

Authors:  Dao-Yao He; Nancy N H McGough; Ajay Ravindranathan; Jerome Jeanblanc; Marian L Logrip; Khanhky Phamluong; Patricia H Janak; Dorit Ron
Journal:  J Neurosci       Date:  2005-01-19       Impact factor: 6.167

3.  Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine.

Authors:  J K Staley; Q Ouyang; J Pablo; W L Hearn; D D Flynn; R B Rothman; K C Rice; D C Mash
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

4.  Long-lasting ibogaine protection against NMDA-induced convulsions in mice.

Authors:  M B Leal; D O de Souza; E Elisabetsky
Journal:  Neurochem Res       Date:  2000-08       Impact factor: 3.996

5.  Glial cell line-derived neurotrophic factor reverses ethanol-mediated increases in tyrosine hydroxylase immunoreactivity via altering the activity of heat shock protein 90.

Authors:  Dao-Yao He; Dorit Ron
Journal:  J Biol Chem       Date:  2008-03-14       Impact factor: 5.157

6.  Effect of ibogaine on serotonergic and dopaminergic interactions in striatum from mice and rats.

Authors:  H Sershen; A Hashim; A Lajtha
Journal:  Neurochem Res       Date:  1994-11       Impact factor: 3.996

7.  The putative anti-addictive drug ibogaine is a competitive inhibitor of [3H]MK-801 binding to the NMDA receptor complex.

Authors:  P Popik; R T Layer; P Skolnick
Journal:  Psychopharmacology (Berl)       Date:  1994-05       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.